



Review

The Interplay between Non-Esterified Fatty Acids and Plasma Zinc and Its Influence on Thrombotic Risk in Obesity and Type 2 Diabetes

Stephen J. Hierons ¹, Jordan S. Marsh ¹, Dongmei Wu ¹, Claudia A. Blindauer ²  and Alan J. Stewart ^{1,*} 

¹ School of Medicine, University of St. Andrews, St. Andrews KY16 9TF, Fife, UK; sh256@st-andrews.ac.uk (S.J.H.); jm451@st-andrews.ac.uk (J.S.M.); dw95@st-andrews.ac.uk (D.W.)

² Department of Chemistry, University of Warwick, Coventry CV4 7AL, UK; c.blindauer@warwick.ac.uk

* Correspondence: ajs21@st-andrews.ac.uk; Tel.: +44-(0)-1334-463546; Fax: +44-(0)-1334-463482

Abstract: Thrombosis is a major comorbidity of obesity and type-2 diabetes mellitus (T2DM). Despite the development of numerous effective treatments and preventative strategies to address thrombotic disease in such individuals, the incidence of thrombotic complications remains high. This suggests that not all the pathophysiological mechanisms underlying these events have been identified or targeted. Non-esterified fatty acids (NEFAs) are increasingly regarded as a nexus between obesity, insulin resistance, and vascular disease. Notably, plasma NEFA levels are consistently elevated in obesity and T2DM and may impact hemostasis in several ways. A potentially unrecognized route of NEFA-mediated thrombotic activity is their ability to disturb Zn^{2+} speciation in the plasma. Zn^{2+} is a potent regulator of coagulation and its availability in the plasma is monitored carefully through buffering by human serum albumin (HSA). The binding of long-chain NEFAs such as palmitate and stearate, however, trigger a conformational change in HSA that reduces its ability to bind Zn^{2+} , thus increasing the ion's availability to bind and activate coagulation proteins. NEFA-mediated perturbation of HSA- Zn^{2+} binding is thus predicted to contribute to the prothrombotic milieu in obesity and T2DM, representing a novel targetable disease mechanism in these disorders.

Keywords: diabetes; human serum albumin; insulin resistance; non-esterified fatty acids; obesity; thrombosis; zinc



Citation: Hierons, S.J.; Marsh, J.S.; Wu, D.; Blindauer, C.A.; Stewart, A.J. The Interplay between Non-Esterified Fatty Acids and Plasma Zinc and Its Influence on Thrombotic Risk in Obesity and Type 2 Diabetes. *Int. J. Mol. Sci.* **2021**, *22*, 10140. <https://doi.org/10.3390/ijms221810140>

Academic Editors:

Jean-François Tanti and Ramzi Ajjan

Received: 30 August 2021

Accepted: 16 September 2021

Published: 20 September 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Obesity and type-2 diabetes mellitus (T2DM) are two closely related disorders, the former being associated with a high body mass index (BMI; $>30 \text{ kg/m}^2$) and the latter with insulin resistance and inadequate glycemic control. Both conditions predispose an individual to vascular complications [1–4]. Increased vascular risk in these diseases is driven by the establishment of a hypercoagulable state of the plasma [5], which can include the formation of intravascular obstructive blood clots (leading to heart attacks and strokes). Such thrombi are formed secondarily to complex interactions between platelets and coagulation proteins (comprising the cellular and protein arms of coagulation, respectively). Both these aspects of coagulation are altered in obesity and T2DM; platelets display hyperactivity, while coagulation proteins circulate at higher concentrations and display enhanced activation, ultimately leading to the formation of compact fibrin networks and impaired fibrinolysis [5,6]. Hypofibrinolysis also represents a key abnormality in obese and diabetic patients and contributes to the adverse clinical outcome in this population [7,8].

In addition to an enhanced thrombotic state, obesity and T2DM are also associated with derangements in lipid metabolism with resulting changes to the plasma lipid profile of affected individuals [9,10]. Of particular interest is the impact of these disease states on the levels of plasma non-esterified fatty acids (NEFAs). As a major reservoir of metabolic energy, one of the primary components of cellular membranes and a precursor to numerous

cellular effectors, plasma NEFA levels can be altered in a variety of disease states. Notably, plasma NEFA levels are frequently elevated in obesity and T2DM [11–15], likely resulting from imbalances between uptake and release of NEFAs by adipocytes. In particular, basal fat cell lipolysis (the hydrolysis of triacylglycerol into fatty acids and glycerol) is elevated in the obese state, resulting in greater release of NEFAs into the blood [16]. Enlarged and metabolically stressed adipose tissue also loses the ability to adequately store fat over time, resulting in greater migration of NEFAs towards ectopic tissues such as the liver and skeletal muscle [17]. Elevations in plasma NEFA levels have relevant pathological implications. Total NEFA concentration is closely related to insulin resistance, and NEFAs may have a causative role in its onset [12,18,19]. Importantly, adipose tissue lipolysis is inhibited by insulin [20], and so this mechanism to control NEFA release is also lost in the diabetic state, likely causing further elevations in plasma NEFA levels.

Plasma NEFA levels are related to unfavorable prognoses in both stroke and cardiovascular disease [21–23] and are likely to contribute to the prothrombotic milieu in obesity and T2DM. Several mechanisms by which NEFAs contribute to thrombosis have already been proposed. These include their ability to induce endothelial dysfunction (and, thus, contribute to atherosclerosis) [24], to alter platelet function [25], and to directly dysregulate fibrin clot structure [26]. Additionally, recent findings also highlight the role of NEFAs as indirect effectors of coagulation through their ability to impact zinc availability in the plasma. Zinc is an essential regulator of coagulation, mediating multiple aspects including platelet aggregation, fibrin clotting, and fibrinolysis [27]. Specifically, these effects are mediated by the free aquo ion of Zn^{2+} . Extracellular Zn^{2+} is bound by human serum albumin (HSA), which serves as the major buffering agent of plasma Zn^{2+} . HSA also binds and transports NEFAs at several sites [28–30] and, importantly, pathophysiological concentrations of these fatty acids (as documented in obesity and T2DM) perturb the ability of HSA to bind and buffer Zn^{2+} [31]. As a consequence of this allostery, Zn^{2+} no longer able to bind HSA has greater freedom to bind and activate clot-forming proteins. It is predicted that sustained prothrombotic signaling by this Zn^{2+} fraction contributes to the greater clotting risk observed in obesity and T2DM [32].

2. Zn^{2+} as a Regulator of Hemostasis

Thrombus formation is the result of hemostasis, a normal physiological process that maintains blood vessel integrity and responds to and blocks vascular breach. The hemostatic mechanism occurs through the actions of both cellular and soluble protein components, namely, platelets and clotting factors, respectively. Platelet activation and aggregation result in the formation of an initial platelet “plug” at the site of vascular damage. In turn, protein clotting factors undergo sequential activation (through the coagulation cascade), culminating in the generation of a fibrin network that stabilizes the platelet aggregate [33]. These two systems (termed primary and secondary hemostasis, respectively) are not separate but instead operate simultaneously, synergistically, and in a linked manner [34,35]. Following early observations that zinc deficiency was associated with bleeding and clotting impairments, research has since identified the Zn^{2+} ion as a ubiquitous agent in the coagulation mechanism [27]. Importantly, free Zn^{2+} has a role in controlling both platelet function and fibrin network formation both directly and indirectly (Figure 1).

The initial response to vascular damage is the attachment and activation of platelets at the site of injury. Activated platelets subsequently aggregate together to form an occluding platelet “plug” (primary hemostasis) to temporarily stop bleeding [35]. Platelets can facilitate this process, along with the generation of fibrin (secondary hemostasis), through the release of numerous pro-coagulant factors that originate from internal stores known as dense and α -granules [35,36]. This latter granule type is the most abundant and is a major store of Zn^{2+} within platelets (containing 40% of total platelet zinc content) [36–38]. Trauma to the vasculature and subsequent loss of endothelial cells results in the presentation of subendothelial molecules (such as collagen, fibronectin, and laminin [39–41]). This creates anchorage sites, further enhanced by the deposition of plasma von Willebrand factor onto

collagen, for platelets to bind [40,42]. Platelet adhesion activates platelets and begins a myriad of processes such as morphological changes and platelet aggregation (through activation of α IIb β 3 integrins [43,44]). Elevated cytosolic Zn^{2+} , which can occur following agonist binding to glycoprotein (GP) VI (a platelet receptor for collagen), has been shown to promote these downstream effects along with dense granule release [45]. Consequently, Zn^{2+} has been proposed as a secondary messenger within platelets [45]. Interestingly, cytosolic Zn^{2+} is also elevated with agonist binding to the thromboxane receptor, a receptor for thromboxane A2 (produced by activated platelets), suggesting that cytosolic Zn^{2+} may be important in both the initial and later stages of platelet activation [45]. Activated platelets mobilize their granules, which fuse with the plasma membrane and the open canicular system (a unique membrane system made up of invaginations) to release their contents into the extracellular space [46]. Transient elevations of free Zn^{2+} in the microenvironment around a site of injury are driven by the release of Zn^{2+} from both activated platelets and nearby damaged cells [38,47]. This free Zn^{2+} can be taken up by nearby resting platelets and, depending on the concentration, can either directly activate platelets or potentiate the response of platelets to other platelet agonists [48]. Circulating fibrinogen can also be bound by neighboring platelets, through the now active α IIb β 3 integrin, linking them together and facilitating thrombus formation and growth [49]. Zn^{2+} , released from platelets, further promotes aggregation by amplifying both the number of fibrinogen binding sites and agonist-induced platelet aggregation [50–52].




Figure 1. The role of Zn^{2+} in hemostasis. Zn^{2+} is an important mediator of hemostasis, affecting several key aspects of the process. Platelet activation and aggregation: Platelets bind to exposed subendothelial molecules and deposited von Willebrand factor. When collagen and thromboxane A2 bind to platelet receptors, glycoprotein (GP) VI and thromboxane receptor (TP), respectively, it is likely that a cytosolic increase in Zn^{2+} results, from α -granules, leading to platelet shape change, granule release, and activation of α IIb β 3. Platelets bind fibrinogen (fg) through their activated α IIb β 3 integrin to aggregate, a process enhanced by Zn^{2+} . Granule release causes increases in extracellular Zn^{2+} , potentiating and activating nearby platelets. Coagulation cascade: Zn^{2+} can directly or indirectly modulate the activity of several coagulation factors. Pro-coagulant effects by Zn^{2+} include the facilitation of the intrinsic pathway through enabling FXII binding to platelet and endothelial surfaces and, in the presence of phospholipid vesicles, attenuating the inhibitory action of activated protein C (APC) on FVa. Anti-coagulant effects by Zn^{2+} include the direct inhibition of FXa production through FVIIa binding, increased binding of protein S to FXa (attenuating its activity) and, in the presence of Ca^{2+} , promotion of APC generation. The coagulation cascade is highlighted in blue, red and purple to illustrate the intrinsic, extrinsic and common pathways respectively. Clot stability and fibrinolysis: Zn^{2+} promotes thrombus longevity by attenuating components of the fibrinolytic system. Created with [BioRender.com](https://www.biorender.com) (accessed 27 August 2021).

During secondary hemostasis, the platelet plug (the final product of primary hemostasis) is stabilized using an interlaced fibrin mesh, which is itself the final product of the coagulation cascade. The coagulation cascade is initiated through two pathways, intrinsic and extrinsic, which merge into a common pathway to facilitate a thrombin spike and, consequently, fibrinogen to fibrin conversion [35]. The intrinsic pathway starts with activation of factor (F) XII, which can occur through autoactivation on negatively charged molecules and surfaces [53]. This includes artificial surfaces, activated platelets, or endothelial cells (with Zn^{2+} an essential cofactor for the former two surfaces) [27,53–56]. Alternatively, Factor XII can be activated through the contact activation system, with Zn^{2+} again a cofactor in the interaction between high-molecular-weight kininogen (HMWK) and FXII with endothelial cells [57,58]. The pathway continues with FXIIa converting FXI to FXIa, which occurs when FXI binds onto the platelet surface (an interaction enhanced by Zn^{2+}) [59,60]. FXIa can then activate FIX, allowing the intrinsic tenase complex to be formed, which subsequently activates FX to meet the extrinsic pathway [60]. In the extrinsic pathway, as blood flows out the damaged site, the circulating FVII encounters tissue factor (TF) and forms the activated complex TF-FVIIa, which can then activate FX [60]. Ultimately, the two coagulation pathways converge and result in thrombin generation, enabling the cleavage of fibrinogen to form fibrin, with Zn^{2+} able to bind to both [60,61]. Interestingly, the absence of the intrinsic coagulation pathway (through congenital FXII deficiency) does not prevent hemostasis and has been implicated in thrombosis (where mice deficient in FXII- or FXI- factors of the intrinsic pathway, displayed a protective effect against thrombosis) [62].

Multiple facets of clot stability, generation, and degradation can be affected by the presence of Zn^{2+} , which decreases fibrin generation time, reduces fibrin stiffness, and produces thicker fibrin fibers [63,64]. Though this last feature can render a thrombus more susceptible to fibrinolysis, Zn^{2+} can inhibit this process by reducing tissue-type plasminogen activator (tPA)-mediated plasminogen activation, and the activity of plasmin [63,64]. Additionally, promotion of the heparin-thrombin-fibrin complex by Zn^{2+} can shield thrombin from inactivation by antithrombin (since heparin binding to both antithrombin and thrombin is required for the latter's inhibition) and enable further fibrin generation to occur [65].

Finally, it is noted that the hemostatic contributions of Zn^{2+} are not solely of a procoagulant nature. Indeed, coagulation can also be attenuated by Zn^{2+} through its action on several proteins, altering their affinities and activities. Zn^{2+} promotes the interaction of HMWK and FXII with GPIb α , a subunit of the GPIb-V-IX complex, resulting in reduced thrombin binding to GPIb α [66,67]. Though thrombin (a potent platelet agonist) can activate platelets without binding GPIb α , it is thought that the maximal effect of thrombin requires this interaction [67]. Additionally, Zn^{2+} amplifies the anti-coagulant effects of protein S, inhibits the pro-coagulant FVIIa, and has a varying coagulant effect on activated protein C (depending on other components present; Figure 1) [27]. Overall, however, several notable observations give prominence to the role of Zn^{2+} as an important effector of coagulation. This includes the ability of Zn^{2+} to regulate platelet aggregation, to act as a cofactor in the coagulation cascade, and to directly alter the properties of the platelet-fibrin thrombus. Given these considerations, the availability of Zn^{2+} in plasma must be adequately controlled to prevent improper activation of Zn^{2+} -mediated coagulation pathways.

3. Control of Plasma Zn^{2+} Availability and the Impact of NEFAs

The task of buffering (and transporting) Zn^{2+} in the blood is overwhelmingly performed by human serum albumin (HSA) [68]. HSA folds into three homologous domains (I, II, and III) and each domain is formed by two subdomains (A and B). HSA is the dominant protein in adult plasma ($\sim 40 \text{ mg mL}^{-1}$ [69]) and is reported to bind 75–85% (9–14 μM) of the Zn^{2+} circulating in the blood [70]. This makes HSA the major regulator of Zn^{2+} “speciation” in the plasma, where speciation refers to the state in which Zn^{2+} is present (bound or unbound; and, if bound, to which partner molecule(s)). HSA possesses two

Zn²⁺-binding sites that have been experimentally identified, namely, site A and B. Site A has been recognized as the primary Zn²⁺-binding site to HSA (with a K_D of 100 nM), while site B is the secondary site (with a K_D in the mid-micromolar range) and is unlikely to contribute greatly to Zn²⁺ binding in vivo [68]. Site A is located at the interface between domains I and II and includes His67 (from domain I) and His247 and Asp249 (from domain II) [71,72]. It has been suggested that site B may also be an interdomain site, composed of residues His9, Asp13 (from domain I), and Asp255 (from domain II) by our previously elucidated structures of Zn²⁺-bound human and equine serum albumin [72].

HSA has a highly dynamic structure, and this dynamicity endows the HSA molecule with considerable binding versatility. In the blood, the protein acts as a repository in which a large variety of endogenous and exogenous molecules may be stored and transported [73]. The binding, transport, and release of its cargos are strongly dependent on HSA conformation, which itself is readily influenced by numerous physiological and pathophysiological conditions including pH, endogenous molecules, and post-translational modifications [74]. Notably, in diabetes, the properties of HSA have been shown to change in a manner that impacts its Zn²⁺-binding ability [75]. Poor glycemic control (in both types I and II diabetes) causes a marked increase in glycosylated HSA levels with concomitant change to both HSA structure and circulatory half-life [76–80]. Using spectrometric and calorimetric approaches, a reduced affinity for Zn²⁺ has been demonstrated in glycosylated HSA [75], potentially due to local unfolding of the protein (in subdomain IIA, which harbors two of the three Zn²⁺-binding residues). Furthermore, a comparison of 11.5% and 65.5% glycosylated HSA (which are in the pathophysiological range [81]) revealed the affinity of the latter for Zn²⁺ to be 2.3-fold lower [82].

In addition to its role as the primary Zn²⁺ carrier, HSA is also the principal transporter of NEFAs in the blood. There are at least seven NEFA-binding sites (FA1-7) on HSA that have been identified by crystallographic studies. These sites are asymmetrically distributed across its three domains, with FA2 (domain I/II interface), FA4, and FA5 (both domain III) considered as the highest-affinity sites [28,29]. Under normal physiological conditions, HSA binds between 0.1–2 molar equivalents (mol. eq.) of NEFAs, depending on metabolic demand. However, HSA is capable of binding much higher NEFA concentrations (up to 6 mol. eq.) in certain pathological conditions, which include T2DM and cardiovascular disease [73]. Multiple studies have demonstrated the ability of NEFAs to influence the ligand-binding properties of HSA [30,83–86]. Notably, recent evidence has indicated that NEFA binding to the FA2 site prevents Zn²⁺ binding at site A, leading to a considerable reduction in Zn²⁺ binding affinity (as summarized in Figure 2A,B). NEFA binding at the FA2 site requires the interaction of residues from both domains I and II. In particular, the methylene tail of the NEFA molecule makes contact with predominantly hydrophobic residues in sub-domains IA and IB. The carboxylate end, meanwhile, is anchored by residues Arg257 and Ser287 from sub-domain IIA and Tyr150 from sub-domain IIB [29]. In apo-HSA, the two half-pockets in the two domains are ~10 Å apart [32,87]. Accommodation of a NEFA molecule requires a substantial domain–domain movement to bring them together. The resulting conformational change also affects subdomain IA and moves the Zn²⁺-coordinating nitrogen of His67 (domain I) approximately 8 Å away from its initial position in the proximity of His247 and Asp249 (domain II), too far to form a viable Zn²⁺-binding site. Thus, NEFA binding at the high-affinity site FA2 prevents coordination of any previously bound Zn²⁺ ion [31,32]. The ability of different NEFAs (octanoate (C8:0), laurate (C12:0), myristate (C14:0), palmitate (C16:0), palmitoleate (C16:1-cis), and stearate (C18:0)) to influence Zn²⁺ binding to HSA has been examined through competition experiments using isothermal titration calorimetry (Figure 2C,D). Addition of up to 5 mol. eq. of octanoate had little effect on Zn²⁺ binding to HSA (it is too short to elicit the conformational switch), but a change was seen with laurate and longer-chain saturated NEFAs, where the results suggested a reduction in the stoichiometry of site A with increasing NEFA concentrations [88].




Figure 2. Influence of fatty acids on HSA structure and zinc binding. (A). X-ray crystal structure of HSA with zinc bound (PDB: 5IJF). Zinc binds in a tetrahedral geometry at site A involving the side chains of His67, His247, and Asp249. (B). X-ray crystal structure of HSA with myristate bound (PDB: 1BJ5). The binding of myristate at the FA2 site causes movement of zinc-binding residue His67 away from His247 and Asp249. (C). Isothermal titration calorimetry showing the effect of fatty acid loading on zinc binding to HSA. In the experiments 1.5 mM $ZnCl_2$ was titrated into 60 μ M HSA, in the presence of either 0 (black), 3 (blue), 4 (green), or 5 (red) mol. eq. of myristate in a buffer containing 50 mM Tris, 140 mM NaCl, pH 7.4. (D). Bar chart representing the availability of binding site A in the presence of 4 mol. eq. of various fatty acids. All except octanoate had large effects on Zn^{2+} binding to the protein. Data for parts C and D were taken from Sobczak et al. [88].

4. Impact of NEFAs on Zn^{2+} -Protein Interactions

NEFAs are clearly capable of reducing the Zn^{2+} -binding ability of HSA. Moreover, recent evidence from Coverdale et al. has demonstrated that this allosteric interaction is sufficient to alter the speciation of Zn^{2+} in plasma [31]. Metalloproteomic analysis of fractionated plasma (in the absence and presence of 5 mol. eq. myristate relative to HSA) revealed the concentration of Zn^{2+} in HSA-containing fractions to be reduced in myristate-treated plasma, with a shift to proteins with higher molecular weight. Thus, it is likely that in conditions of obesity and T2DM (where plasma NEFA levels are consistently elevated) Zn^{2+} speciation is chronically disrupted. Altered Zn^{2+} speciation and, hence, dynamics brought about by elevated plasma NEFA may ultimately have the potential to trigger and/or potentiate thrombotic events, thus constituting a novel mechanism of thrombosis in obesity and T2DM. Zn^{2+} ions not able to bind to HSA may drive thrombus formation by acting on fibrin clot formation and lysis directly, for example, by increasing the rate of clot formation (thus enhancing clot stability) or by delaying clot lysis through attenuation of plasmin-mediated fibrin degradation [32]. A rise in non-HSA-bound Zn^{2+} may also increase Zn^{2+} uptake/flux by endothelial cells, leukocytes, and platelets via zinc transporter proteins [32,48,89]. For platelets, this small elevation in free Zn^{2+} may be enough to sensitize them to other agonists and cause inappropriate activation [48]. Additionally, in the event of reduced Zn^{2+} binding by HSA, it is likely this Zn^{2+} binds other plasma proteins including those that mediate thrombosis in a Zn^{2+} -dependent manner.

There are several coagulation-related, Zn^{2+} -binding plasma proteins that may bind an increased proportion of Zn^{2+} when HSA- Zn^{2+} interactions are compromised by NEFA binding. These include plasminogen, plasmin, tPA, fibrinogen, factor XIII, and histidine-rich glycoprotein (HRG) [31,38,63,90]. The last three proteins, in combination with HSA, are all constituents of α -granules and their local plasma levels transiently increase locally at the surface of activated platelets [38,91]. HRG is particularly relevant as Zn^{2+} modulates its affinity toward other coagulation proteins, impacting their functioning. HRG is relatively abundant in human plasma (ca. 1.5 μ M), although this value is often elevated in cardiovascular disease [92,93]. HRG is well suited to binding divalent metal ions owing to its histidine-rich region, which possesses 10 binding sites for Zn^{2+} ($K_D = 1.63 \times 10^5$) [94]. These considerations make it a likely candidate protein to bind Zn^{2+} prevented from binding to HSA by elevated NEFAs. Furthermore, modelling of Zn^{2+} speciation has supported the hypothesis that HRG can pick up HSA-free Zn^{2+} [94]. Finally, both these *a priori* and modelling assumptions are supported by the Coverdale et al. study, which found greater levels of Zn^{2+} present in HRG-containing plasma fractions upon addition of myristate [31]. HRG has several important binding partners that regulate homeostatic processes, such as activated Factor XIIa, plasminogen, fibrinogen, fibrin, and heparin. HRG can regulate coagulation through these interactions and, importantly, these interactions are enhanced in the presence of Zn^{2+} [95–97]. HRG can counter the anticoagulant effects of heparin, upon binding, by reducing the availability of heparin for antithrombin, thereby enabling thrombin activity to continue [95]. Interestingly, heparin neutralization can also be achieved through its complexation with fibrinogen and, notably, this interaction is also enhanced in the presence of Zn^{2+} . Fibrinogen binds Zn^{2+} with a K_D of 9 μ M and it, therefore, may represent another possible Zn^{2+} -binding partner when plasma NEFA levels are elevated [98]. Thus, reduced Zn^{2+} buffering may also enhance thrombotic risk in the obese and diabetic states through enhanced complexation of HRG-heparin and/or fibrinogen-heparin with resulting impairment to heparin-mediated anti-coagulation [32].

To fully understand the impact of NEFAs on Zn^{2+} -dependent coagulation, further work is required to fully elucidate changes in plasma Zn^{2+} speciation in the presence of elevated NEFAs' concentrations. Some approaches have been developed to examine such "speciomic" changes in metals in complex systems such as plasma. Laser ablation-inductively coupled plasma mass spectrometry in combination with 2D-polyacrylamide gel electrophoresis can be used to analyze the proportion of Zn^{2+} associated with specific proteins following separation on a gel. This approach has already been successfully employed to examine the association of different metals with metalloproteins in plasma [99]. Similarly, proteins bound to individual metals can be identified through chromatographic fractionation (under near-native conditions) using gel filtration and/or ion-exchange chromatography. The individual proteins in fractions can be subsequently identified by gel electrophoresis/mass spectrometry and metal concentrations within fractions by inductively coupled plasma mass spectrometry, with individual metal-protein interactions inferred from principal component analyses of the resulting data [100]. Such methods may be employed to identify plasma coagulation proteins that bind a higher proportion of Zn^{2+} in the presence of high concentrations of NEFAs.

5. Evidence for the Zn^{2+} -NEFA Switch as a Thrombotic Mechanism

There is indirect evidence available that suggests altered Zn^{2+} dynamics may play a role in thrombotic disease. Such evidence includes the observation that analbuminemia (HSA deficiency) is associated with hypercoagulability [101]. While this is likely to be a result of a combination of factors, including altered concentrations of coagulation proteins, it is apparent that this would impact plasma Zn^{2+} availability (potentially increasing the proportion of Zn^{2+} able to bind coagulation proteins) and, thus, Zn^{2+} -dependent hemostasis. In the opposite manner, it can be assumed that conditions that would potentially decrease the availability of Zn^{2+} for coagulation proteins should beneficially impact cardiovascular health. It is noted that many effective medications for diabetes

have chelating properties [102–105] and, thus, it is conceivable that chelation of Zn^{2+} from prothrombotic proteins by these agents contributes in their ability to lower cardiovascular risk. Additional support for this assumption may be provided by recent findings from the trial to assess chelation therapy (TACT). Chelation therapy involves the intravenous or oral administration of chelating agents to remove metal ions from the blood. The use of chelation therapy remains controversial and, up until 2002, no large-scale clinical trial had existed that could independently ascertain whether the practice impacted favorably on cardiovascular risk in certain groups [106]. TACT was employed to study the safety and efficacy of EDTA-based chelation in a post-myocardial infarction (MI) population. Treatment involved 40 weekly infusions with either the active chelating agent or a saline solution [107]. Overall, participants receiving the chelation infusion had an 18% reduced risk of reaching the primary endpoint (a composite of death from any cause, myocardial infarction, stroke, coronary revascularization, and hospitalization for angina) compared to those receiving the placebo infusion ($p = 0.035$) [108]. Approximately one-third of the patients studied in TACT had T2DM and, intriguingly, this subgroup was shown to derive the most benefit from the EDTA-based infusions. Indeed, the risk of the combined primary endpoint was reduced by 41% in T2DM patients receiving EDTA infusion compared to those receiving the placebo ($p < 0.001$). There was additionally a 52% relative reduction in the risk of recurrent MI ($p = 0.015$) and a 43% relative reduction in the risk of death from any cause ($p = 0.011$) [109]. This reported benefit may conceivably occur, at least in part, through chelation of non-HSA-bound Zn^{2+} and prevention of its binding to clot-forming proteins.

Several pieces of evidence suggest that NEFA-mediated alterations in Zn^{2+} speciation represent a potential contributory mechanism for thrombosis in obesity and T2DM. Our recent work suggests NEFA and Zn^{2+} can act synergistically in homeostatic processes relating to platelet aggregation, fibrin clotting, and fibrinolysis [88]. The evidence of this synergism has come largely from ex vivo and in vitro approaches. Indeed, we recently addressed the question of whether NEFAs alter fibrin clot formation and lysis in a Zn^{2+} -dependent manner using turbidimetric studies that utilized either purified proteins (fibrinogen and HSA) or plasma, with clotting initiated by the addition of thrombin in both systems. Irrespective of the system studied, the maximum absorbance (indicative of the size and density of the clot formed) increased with Zn^{2+} at concentrations of 20–100 μ M, with the addition of myristate having a synergistic effect on this parameter [88]. Moreover, turbidimetric analysis of plasma samples taken from age- and sex-matched groups of individuals with T2DM and controls (without diabetes) was performed, and the plasma concentrations of major NEFA species in the samples were measured using GC-MS. Clot density was significantly higher in the diabetic cohort, which also had significantly higher plasma NEFA concentrations. The positive association between clot density and NEFA concentration thus mirrored the effect of NEFAs on clot parameters observed in turbidimetric assays. The NEFAs myristate, palmitate, linolenate (18:3), oleate (18:1c9), *cis*-vaccenate (18:1c11), stearate, eicosapentaenoate (20:5), and arachidonate (20:4) were elevated in the T2DM group. The concentrations of myristate, palmitate, oleate, *cis*-vaccenate, and stearate positively correlated with maximum absorbance, supporting the concept that elevated NEFA levels contribute to increased thrombotic risk in T2DM, potentially through mishandling of plasma Zn^{2+} . In the same study, the effects of Zn^{2+} and NEFAs on platelet aggregation were examined in vitro. The presence of myristate (but not octanoate, which does not significantly affect Zn^{2+} -binding to HSA) increased maximum aggregation in a concentration-dependent manner (addition of 4 mol. eq. myristate significantly increased maximum aggregation in platelets-in-plasma) and this effect was potentiated by the addition of (100 μ M) Zn^{2+} . Most crucially, addition of the metal chelator *N,N,N',N'*-tetrakis(2-pyridinylmethyl)-1,2-ethanediamine (TPEN) abolished not only the effect of Zn^{2+} but also that of the NEFA. This provides strong evidence that the effect of NEFA on platelet aggregation was mediated by its ability to displace Zn^{2+} from HSA. Thus, it appears likely that the allosteric mechanism that mediates cross-talk between Zn^{2+} and

NEFA binding first identified in simple model systems operates in real plasma [94,110], that NEFAs induce changes in Zn^{2+} speciation [31], and that these changes drive prothrombotic events in obesity and T2DM [88].

6. NEFAs a Target for Therapy

Reduced Zn^{2+} buffering by NEFAs represents a likely pathophysiological mechanism linking elevated plasma NEFA levels to increased risk of thrombotic complications in obesity and T2DM. Thus, lowering plasma NEFA concentrations in these groups is likely to be of great clinical usefulness. Removal of excess adiposity via caloric restriction and physical activity is an established method of improving cardiovascular health among obese and diabetic obese individuals [111]. Appropriate exercise and nutrition impact favorably on cardiovascular risk markers including lipid profile and, importantly, a diet- and exercise-mediated return to metabolic normality is predicted to lower plasma NEFA levels. Bariatric surgery in obese individuals also leads to marked decreases in plasma NEFAs after 6 months [112–115]. In addition to these strategies, it may be possible to leverage the pleiotropic actions of current diabetes medications, given that treatment with these agents also has the potential to lower plasma NEFA concentrations.

One aspect of T2DM treatment involves the pharmacological management of diabetic dyslipidemia in which lipid-lowering drugs including statins and fibrates are commonly employed [116]. The ability of these agents to lower the incidence of cardiovascular events is supported by numerous randomized clinical outcome studies [117]. Their clinical benefit has been mainly attributed to their ability to impact on total plasma cholesterol (TC), low-density lipoprotein (LDL), and high-density lipoprotein (HDL) concentrations. However, it is apparent that these drugs also influence plasma NEFA levels and thus it is possible that they could be used to “normalize” elevated NEFA concentrations in obesity and T2DM. Statins are the most employed agents for the treatment of diabetic dyslipidemia. These drugs decrease plasma cholesterol levels by competitively inhibiting hydroxymethylglutaryl-CoA reductase, the principal rate-limiting enzyme in cholesterol biosynthesis. Statins also lower plasma cholesterol levels indirectly by increasing the expression of LDL receptors on cell surfaces, resulting in greater LDL uptake. Additionally, a recent meta-analysis has shown that these agents can significantly lower total plasma NEFA levels in individuals with T2DM, metabolic syndrome, or dyslipidemia [118]. Fibrates or fibrates are employed secondarily to statin therapy. These agents act primarily by activating the peroxisome proliferator-activated receptor- α (PPAR- α) which leads to an increase in NEFA oxidation and decreased triglyceride synthesis in the liver [119]. Several studies have investigated the effect of fibrate treatment on total plasma NEFA levels in different populations, which included individuals with various metabolic derangements (healthy subjects and subjects with T2DM, hypolipoproteinemia, hyperinsulinemia, hypertriglyceridemia, glucose intolerance, or metabolic syndrome) [120–134]. In all studies, plasma NEFA levels were found to be either unchanged or reduced except for a single study [128], in which fibrate treatment increased NEFA levels in individuals with hypertriglyceridemia and glucose intolerance.

Normalizing blood glucose concentrations represents another goal in the management of diabetes. This aspect of management involves the use of antihyperglycemic drugs such as metformin, sodium-glucose cotransporter 2 (SGLT) inhibitors, and glucagon-like peptide 1 (GLP-1) receptor agonists. Metformin is often the first choice of glucose-lowering drugs for T2DM patients. The drug improves insulin sensitivity by inhibiting gluconeogenesis in the liver [135]. Most studies, however, do not recognize any effect of metformin on plasma NEFA concentrations [136–139] and, thus, this agent is an unsuitable candidate for lowering NEFA levels in diabetic and obese diabetic patients. Interestingly, the ability of metformin to confer true cardiovascular benefit has come into question in recent years [140,141]. Meta-analyses have shown metformin was unable to confer significant benefit to all-cause mortality, cardiovascular mortality, MI, peripheral vascular disease, or stroke in T2D patients. GLP-1 receptor agonists and SGLT-2 inhibitors are two

new classes of antihyperglycemic drugs that are both very effective at lowering blood glucose levels [142]. Additionally, these drugs also have numerous pleiotropic actions that may endow them with NEFA-lowering properties [143,144]. Glucagon-like peptide 1 (GLP-1) receptor agonists stimulate release of insulin from the pancreas in response to oral and intravenous glucose [145]. The GLP-1 agonist liraglutide has been demonstrated to be superior to placebo in reducing the primary composite of time to death, non-fatal MI, and non-fatal stroke in high-risk cardiovascular patients [146]. Two recent meta-analyses have additionally demonstrated that liraglutide beneficially influences lipid status in T2DM patients, causing significant reductions in TC, LDL, triglycerides (TG), and NEFAs [147,148]. Like GLP-1 receptor agonists, SGLT-2 inhibitors help to regulate glycemic control. These agents stimulate glycosuria (the excretion of glucose into the urine) by inhibiting SGLT-2-mediated glucose reabsorption in the proximal tubule of the kidneys [145,149]. T2DM patients treated with the SGLT-2 inhibitor empagliflozin have a reduced risk of the primary composite outcome of cardiovascular disease-related death, non-fatal MI, and stroke compared to T2DM patients receiving placebo [150]. Importantly, SGLT-2 inhibitors are predicted to lower plasma NEFA levels, given their ability to activate PPAR- α and, thus, promote fatty acid oxidation in a similar manner to fibrates [151].

Alternatively, it is noted that this prothrombotic mechanism could be targeted more specifically by employing inhibitors that selectively bind to the FA2 site of HSA in a manner that prevents NEFA binding but does not disrupt Zn^{2+} binding to site A. These inhibitors would, thus, protect the Zn^{2+} -binding capacity of HSA at high NEFA concentrations, while still allowing the protein to carry NEFAs via its other binding sites. Importantly, prior to any potential therapeutic use, these molecules should first be used to assess the degree to which the NEFA- Zn^{2+} switch contributes to the prothrombotic state in obesity and T2DM. Indeed, to clarify the relevance of this mechanism, inhibitors directed against the FA2 site could be tested using coagulation assays in animal models. In particular, the potential protective effects of these molecules on fibrin clot formation/lysis and platelet function in the presence of different Zn^{2+} and NEFA concentrations should be ascertained. A summary of the mechanisms by which NEFAs impact on HSA-bound Zn^{2+} and how these may be targeted are shown in Figure 3.




Figure 3. Potential Zn^{2+} -mediated thrombotic routes in obesity and T2DM and targets for therapy. Altered lipid metabolism in obesity and T2DM results in elevated NEFA levels in the blood. NEFA binding at the FA2 site of HSA prevents procoagulant Zn^{2+} ions from binding at site A. The Zn^{2+} unable to bind HSA is redistributed among the cellular and protein components of the homeostatic mechanism, resulting in thrombotic events. This mechanism of thrombosis can be targeted by using lipid- and glucose-lowering drugs, which lower plasma NEFA levels. Therapeutics with chelating properties may also have potential to prevent free Zn^{2+} ions interacting with homeostatic components. FA2 inhibitors could also be developed to restore Zn^{2+} buffering by HSA. Created with [BioRender.com](https://www.biorender.com) (accessed on 13 September 2021).

7. Conclusions

Current evidence indicates that plasma NEFAs impact Zn^{2+} speciation via an allosteric mechanism (occurring at the FA2 site) on HSA in obese and T2DM disease states. In addition to the established mechanisms of NEFA-induced thrombogenesis, this dynamic is likely to contribute to thrombotic complications observed in these diseases. Further work is needed to identify the impact of certain NEFAs on Zn^{2+} -HSA binding, particularly unsaturated NEFAs that have not yet been investigated in this context. In addition, mixtures of NEFAs that represent in vivo concentrations (in health and disease) should be investigated. Zn^{2+} is an important regulator of hemostasis and acts through multiple mechanisms to control coagulation. Knowledge of specific pathways through which it can act has come from in vitro and ex vivo studies. It is unclear which specific proteins or pathways may be activated by non-HSA-bound Zn^{2+} in vivo. However, methods exist to explore Zn^{2+} speciation in relevant systems to better understand which are of the most significance in thrombotic disease. Specific control of plasma NEFA levels, Zn^{2+} availability, or, indeed, Zn^{2+} -dependent coagulatory processes are largely overlooked as pharmacotherapeutic strategies to limit cardiovascular events in at-risk populations. While appropriate nutrition and exercise are potential approaches to lower plasma NEFAs, a future strategy may be to exploit the pleiotropic effects of currently marketed drugs for the treatment of obesity and T2DM, given that many of these agents show NEFA-lowering properties outside of their primary mechanism of action. Additionally, when designing new obesity and T2DM therapeutics, greater focus should be placed on the ability of these drugs to control NEFA levels in addition to more established risk markers such as cholesterol, HDL, and LDL. Insights from TACT have revealed a potential benefit of chelation to cardiovascular health in high-risk groups and, therefore, future therapies for obesity and T2DM could also make

use of compounds with chelating properties. These agents may exert their beneficial effect by blocking non-HSA-bound Zn^{2+} from interacting with components of hemostasis. Finally, more specific strategies that selectively target NEFA binding to FA2 or Zn^{2+} -mediated interactions between macromolecules can potentially be developed. Such agents could be useful for the treatment or management of thrombotic complications and be employed as tools in studies designed to assess the degree to which NEFA-mediated alterations in plasma Zn^{2+} dynamics contribute to thrombotic disorders in high-risk groups.

Author Contributions: Conceptualization, S.J.H. and A.J.S.; writing, S.J.H., D.W., J.S.M. and A.J.S.; review and editing, S.J.H., A.J.S. and C.A.B. All authors have read and agreed to the published version of the manuscript.

Funding: This work was funded by the British Heart Foundation (grant numbers: FS/20/3/34956 and FS/19/69/34639), the China Scholarship Council, and the Leverhulme Trust (grant number: RPG-2017-214).

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Blokhin, I.O.; Lentz, S.R. Mechanisms of thrombosis in obesity. *Curr. Opin. Hematol.* **2013**, *20*, 437–444. [[CrossRef](#)]
2. Erbey, J.R.; Kuller, L.H.; Becker, D.J.; Orchard, T.J. The association between a family history of type 2 diabetes and coronary artery disease in a type 1 diabetes population. *Diabetes Care* **1998**, *21*, 610–614. [[CrossRef](#)]
3. Pearson, S.M.; Whittam, B.; Kulavarasalingam, K.; Mitchell-Gears, A.; James, C.; Ajjan, R.A. Reduction in cardiovascular mortality following severe hypoglycemia in individuals with type 2 diabetes: The role of a pragmatic and structured intervention: Structured intervention for community hypoglycemia. *Cardiovasc. Diabetol.* **2021**, *20*, 18. [[CrossRef](#)] [[PubMed](#)]
4. Roglic, G.; Colhoun, H.M.; Stevens, L.K.; Lemkes, H.H.; Manes, C.; Fuller, J.H. Parental history of hypertension and parental history of diabetes and microvascular complications in insulin-dependent diabetes mellitus: The EURODIAB IDDM Complications Study. *Diabet. Med.* **1998**, *15*, 418–426. [[CrossRef](#)]
5. Sobczak, A.I.S.; Stewart, A.J. Coagulatory Defects in Type-1 and Type-2 Diabetes. *Int. J. Mol. Sci.* **2019**, *20*, 6345. [[CrossRef](#)] [[PubMed](#)]
6. Alzahrani, S.H.; Ajjan, R.A. Coagulation and fibrinolysis in diabetes. *Diabetes Vasc. Dis. Res.* **2010**, *7*, 260–273. [[CrossRef](#)]
7. Sumaya, W.; Parker, W.A.E.; Judge, H.M.; Hall, I.R.; Orme, R.C.; Adam, Z.; Richardson, J.D.; Rothman, A.M.K.; Morgan, K.P.; Gunn, J.P.; et al. Prolonged enoxaparin therapy compared with standard-of-care antithrombotic therapy in opiate-treated patients undergoing primary percutaneous coronary intervention. *Platelets* **2021**, *32*, 555–559. [[CrossRef](#)]
8. Sumaya, W.; Wallentin, L.; James, S.K.; Siegbahn, A.; Gabrysch, K.; Bertilsson, M.; Himmelmann, A.; Ajjan, R.A.; Storey, R.F. Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: A PLATO substudy. *Eur. Heart J.* **2018**, *39*, 1078–1085. [[CrossRef](#)]
9. Howard, B.V.; Ruotolo, G.; Robbins, D.C. Obesity and dyslipidemia. *Endocrinol. Metab. Clin. N. Am.* **2003**, *32*, 855–867. [[CrossRef](#)]
10. Schofield, J.D.; Liu, Y.; Rao-Balakrishna, P.; Malik, R.A.; Soran, H. Diabetes Dyslipidemia. *Diabetes Ther.* **2016**, *7*, 203–219. [[CrossRef](#)]
11. Bjorntorp, P.; Bergman, H.; Varnauskas, E. Plasma free fatty acid turnover rate in obesity. *Acta Med. Scand.* **1969**, *185*, 351–356. [[CrossRef](#)]
12. Boden, G. Obesity and free fatty acids. *Endocrinol. Metab. Clin. N. Am.* **2008**, *37*, 635–646. [[CrossRef](#)] [[PubMed](#)]
13. Carlsson, M.; Wessman, Y.; Almgren, P.; Groop, L. High levels of nonesterified fatty acids are associated with increased familial risk of cardiovascular disease. *Arterioscler. Thromb. Vasc. Biol.* **2000**, *20*, 1588–1594. [[CrossRef](#)]
14. Frohnert, B.I.; Jacobs, D.R.; Steinberger, J.; Moran, A.; Steffen, L.M.; Sinaiko, A.R. Relation between serum free fatty acids and adiposity, insulin resistance, and cardiovascular risk factors from adolescence to adulthood. *Diabetes* **2013**, *62*, 3163–3169. [[CrossRef](#)]
15. Sobczak, A.I.S.; Blindauer, C.A.; Stewart, A.J. Changes in plasma free fatty acids associated with type-2 diabetes. *Nutrients* **2019**, *11*, 2022. [[CrossRef](#)]
16. Morigny, P.; Houssier, M.; Mouisel, E.; Langin, D. Adipocyte lipolysis and insulin resistance. *Biochimie* **2016**, *125*, 259–266. [[CrossRef](#)] [[PubMed](#)]
17. Longo, M.; Zatterale, F.; Naderi, J.; Parrillo, L.; Formisano, P.; Raciti, G.A.; Beguinot, F.; Miele, C. Adipose tissue dysfunction as determinant of obesity-associated metabolic complications. *Int. J. Mol. Sci.* **2019**, *20*, 2358. [[CrossRef](#)] [[PubMed](#)]
18. Mahendran, Y.; Cederberg, H.; Vangipurapu, J.; Kangas, A.J.; Soinenen, P.; Kuusisto, J.; Uusitupa, M.; Ala-Korpela, M.; Laakso, M. Glycerol and fatty acids in serum predict the development of hyperglycemia and type 2 diabetes in Finnish men. *Diabetes Care* **2013**, *36*, 3732–3738. [[CrossRef](#)]

19. Salgin, B.; Ong, K.K.; Thankamony, A.; Emmett, P.; Wareham, N.J.; Dunger, D.B. Higher fasting plasma free fatty acid levels are associated with lower insulin secretion in children and adults and a higher incidence of type 2 diabetes. *J. Clin. Endocrinol. Metab.* **2012**, *97*, 3302–3309. [[CrossRef](#)] [[PubMed](#)]
20. Chakrabarti, P.; Kim, J.Y.; Singh, M.; Shin, Y.K.; Kim, J.; Kumbrink, J.; Wu, Y.; Lee, M.J.; Kirsch, K.H.; Fried, S.K.; et al. Insulin inhibits lipolysis in adipocytes via the evolutionarily conserved mTORC1-Egr1-ATGL-mediated pathway. *Mol. Cell. Biol.* **2013**, *33*, 3659–3666. [[CrossRef](#)] [[PubMed](#)]
21. Choi, J.-Y.; Kim, J.-S.; Kim, J.H.; Oh, K.; Koh, S.-B.; Seo, W.-K. High free fatty acid level is associated with recurrent stroke in cardioembolic stroke patients. *Neurology* **2014**, *82*, 1142–1148. [[CrossRef](#)] [[PubMed](#)]
22. Duan, X.X.; Zhang, G.P.; Wang, X.B.; Yu, H.; Wu, J.L.; Liu, K.Z.; Wang, L.; Long, X. Elevated Serum and Cerebrospinal Fluid Free Fatty Acid Levels Are Associated with Unfavorable Functional Outcome in Subjects with Acute Ischemic Stroke. *Mol. Neurobiol.* **2017**, *54*, 1677–1683. [[CrossRef](#)]
23. Xiong, Z.; Xu, H.; Huang, X.; Arnlov, J.; Qureshi, A.R.; Cederholm, T.; Sjogren, P.; Lindholm, B.; Riserus, U.; Carrero, J.J. Nonesterified fatty acids and cardiovascular mortality in elderly men with CKD. *Clin. J. Am. Soc. Nephrol.* **2015**, *10*, 584–591. [[CrossRef](#)] [[PubMed](#)]
24. Ghosh, A.; Gao, L.; Thakur, A.; Siu, P.M.; Lai, C.W.K. Role of free fatty acids in endothelial dysfunction. *J. Biomed. Sci.* **2017**, *24*, 50. [[CrossRef](#)] [[PubMed](#)]
25. Dhindsa, S.; Ghanim, H.; Dandona, P. Nonesterified fatty acids, albumin, and platelet aggregation. *Diabetes* **2015**, *64*, 703–705. [[CrossRef](#)]
26. Tanka-Salamon, A.; Komorowicz, E.; Szabo, L.; Tenekedjiev, K.; Kolev, K. Free Fatty Acids Modulate Thrombin Mediated Fibrin Generation Resulting in Less Stable Clots. *PLoS ONE* **2016**, *11*, e0167806. [[CrossRef](#)]
27. Vu, T.T.; Fredenburgh, J.C.; Weitz, J.I. Zinc: An important cofactor in haemostasis and thrombosis. *Thromb. Haemost.* **2013**, *109*, 421–430. [[CrossRef](#)]
28. Bhattacharya, A.A.; Grune, T.; Curry, S. Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin. *J. Mol. Biol.* **2000**, *303*, 721–732. [[CrossRef](#)]
29. Curry, S.; Mandelkow, H.; Brick, P.; Franks, N. Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites. *Nat. Struct. Biol.* **1998**, *5*, 827–835. [[CrossRef](#)] [[PubMed](#)]
30. Petitpas, I.; Grüne, T.; Bhattacharya, A.A.; Curry, S. Crystal structures of human serum albumin complexed with monounsaturated and polyunsaturated fatty acids. *J. Mol. Biol.* **2001**, *314*, 955–960. [[CrossRef](#)]
31. Coverdale, J.P.; Barnett, J.P.; Adamu, A.H.; Griffiths, E.J.; Stewart, A.J.; Blindauer, C.A. A metalloproteomic analysis of interactions between plasma proteins and zinc: Elevated fatty acid levels affect zinc distribution. *Metallomics* **2019**, *11*, 1805–1819. [[CrossRef](#)]
32. Coverdale, J.P.; Khazaipoul, S.; Arya, S.; Stewart, A.J.; Blindauer, C.A. Crosstalk between zinc and free fatty acids in plasma. *Biochim. Biophys. Acta Mol. Cell Biol. Lipids* **2019**, *1864*, 532–542. [[CrossRef](#)]
33. Palta, S.; Saroa, R.; Palta, A. Overview of the coagulation system. *Indian J. Anaesth.* **2014**, *58*, 515–523. [[CrossRef](#)] [[PubMed](#)]
34. Falati, S.; Gross, P.; Merrill-Skoloff, G.; Furie, B.C.; Furie, B. Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse. *Nat. Med.* **2002**, *8*, 1175–1181. [[CrossRef](#)]
35. Periyah, M.H.; Halim, A.S.; Mat Saad, A.Z. Mechanism Action of Platelets and Crucial Blood Coagulation Pathways in Hemostasis. *Int. J. Hematol. Oncol. Stem Cell Res.* **2017**, *11*, 319–327. [[PubMed](#)]
36. Blair, P.; Flaumenhaft, R. Platelet alpha-granules: Basic biology and clinical correlates. *Blood Rev.* **2009**, *23*, 177–189. [[CrossRef](#)] [[PubMed](#)]
37. Gorodetsky, R.; Mou, X.; Blankenfeld, A.; Marx, G. Platelet multielemental composition, lability, and subcellular localization. *Am. J. Hematol.* **1993**, *42*, 278–283. [[CrossRef](#)] [[PubMed](#)]
38. Marx, G.; Korner, G.; Mou, X.; Gorodetsky, R. Packaging zinc, fibrinogen, and factor XIII in platelet α -granules. *J. Cell. Physiol.* **1993**, *156*, 437–442. [[CrossRef](#)] [[PubMed](#)]
39. Baumgartner, H.R.; Haudenschild, C. Adhesion of platelets to subendothelium. *Ann. N. Y. Acad. Sci.* **1972**, *201*, 22–36. [[CrossRef](#)]
40. Beumer, S.; Heijnen, H.F.; MJ, I.J.; Orlando, E.; de Groot, P.G.; Sixma, J.J. Platelet adhesion to fibronectin in flow: The importance of von Willebrand factor and glycoprotein Ib. *Blood* **1995**, *86*, 3452–3460. [[CrossRef](#)]
41. Hindriks, G.; Ijsseldijk, M.; Sonnenberg, A.; Sixma, J.; De Groot, P.G. Platelet adhesion to laminin: Role of Ca^{2+} and Mg^{2+} ions, shear rate, and platelet membrane glycoproteins. *Blood* **1992**, *79*, 928–935. [[CrossRef](#)]
42. Tomokiyo, K.; Kamikubo, Y.; Hanada, T.; Araki, T.; Nakatomi, Y.; Ogata, Y.; Jung, S.M.; Nakagaki, T.; Moroi, M. Von Willebrand factor accelerates platelet adhesion and thrombus formation on a collagen surface in platelet-reduced blood under flow conditions. *Blood* **2005**, *105*, 1078–1084. [[CrossRef](#)]
43. Huang, J.; Li, X.; Shi, X.; Zhu, M.; Wang, J.; Huang, S.; Huang, X.; Wang, H.; Li, L.; Deng, H. Platelet integrin $\alpha\text{IIb}\beta\text{3}$: Signal transduction, regulation, and its therapeutic targeting. *J. Hematol. Oncol.* **2019**, *12*, 1–22. [[CrossRef](#)]
44. White, J.G. Fine structural alterations induced in platelets by adenosine diphosphate. *Blood* **1968**, *31*, 604–622. [[CrossRef](#)]
45. Ahmed, N.S.; Lopes Pires, M.E.; Taylor, K.A.; Pugh, N. Agonist-Evoked Increases in Intra-Platelet Zinc Couple to Functional Responses. *Thromb. Haemost.* **2019**, *119*, 128–139. [[CrossRef](#)] [[PubMed](#)]
46. Sharda, A.; Flaumenhaft, R. The life cycle of platelet granules. *F1000Res.* **2018**, *7*, 236. [[CrossRef](#)] [[PubMed](#)]
47. Sharir, H.; Zinger, A.; Nevo, A.; Sekler, I.; Hershinkel, M. Zinc released from injured cells is acting via the Zn^{2+} -sensing receptor, ZnR, to trigger signaling leading to epithelial repair. *J. Biol. Chem.* **2010**, *285*, 26097–26106. [[CrossRef](#)] [[PubMed](#)]

48. Watson, B.R.; White, N.A.; Taylor, K.A.; Howes, J.-M.; Malcor, J.-D.M.; Bihan, D.; Sage, S.O.; Farndale, R.W.; Pugh, N. Zinc is a transmembrane agonist that induces platelet activation in a tyrosine phosphorylation-dependent manner. *Metallomics* **2016**, *8*, 91–100. [[CrossRef](#)]
49. Podolnikova, N.P.; Yakovlev, S.; Yakubenko, V.P.; Wang, X.; Gorkun, O.V.; Ugarova, T.P. The interaction of integrin α IIb β 3 with fibrin occurs through multiple binding sites in the α IIb β -propeller domain. *J. Biol. Chem.* **2014**, *289*, 2371–2383. [[CrossRef](#)]
50. Heyns, A.d.P.; Eldor, A.; Yarom, R.; Marx, G. Zinc-induced platelet aggregation is mediated by the fibrinogen receptor and is not accompanied by release or by thromboxane synthesis. *Blood* **1985**, *66*, 213–219. [[CrossRef](#)]
51. Kowalska, M.A.; Juliano, D.; Trybulec, M.; Lu, W.; Niewiarowski, S. Zinc ions potentiate adenosine diphosphate-induced platelet aggregation by activation of protein kinase C. *J. Lab. Clin. Med.* **1994**, *123*, 102–109.
52. Trybulec, M.; Kowalska, M.A.; McLane, M.A.; Silver, L.; Lu, W.; Niewiarowski, S. Exposure of platelet fibrinogen receptors by zinc ions: Role of protein kinase C. *Proc. Soc. Exp. Biol. Med.* **1993**, *203*, 108–116. [[CrossRef](#)]
53. Mammadova-Bach, E.; Braun, A. Zinc homeostasis in platelet-related diseases. *Int. J. Mol. Sci.* **2019**, *20*, 5258. [[CrossRef](#)]
54. Chaudhry, S.A.; Serrata, M.; Tomczak, L.; Higgins, S.; Ryu, J.; Laprise, D.; Enjyoji, K.; Bekendam, R.; Kaushik, V.; Flaumenhaft, R. Cationic zinc is required for factor XII recruitment and activation by stimulated platelets and for thrombus formation in vivo. *J. Thromb. Haemost.* **2020**, *18*, 2318–2328. [[CrossRef](#)]
55. Schousboe, I. Contact activation in human plasma is triggered by zinc ion modulation of factor XII (Hageman factor). *Blood Coagul. Fibrinolysis* **1993**, *4*, 671–678. [[CrossRef](#)] [[PubMed](#)]
56. Schousboe, I. Endothelial cells express a matrix protein which binds activated factor XII in a zinc-independent manner. *Thromb. Haemost.* **2006**, *95*, 312–319. [[CrossRef](#)]
57. Mahdi, F.; Madar, Z.S.; Figueroa, C.D.; Schmaier, A.H. Factor XII interacts with the multiprotein assembly of urokinase plasminogen activator receptor, gC1qR, and cytokeratin 1 on endothelial cell membranes. *Blood* **2002**, *99*, 3585–3596. [[CrossRef](#)] [[PubMed](#)]
58. Zhao, Y.; Qiu, Q.; Mahdi, F.; Shariat-Madar, Z.; Røjkjær, R.; Schmaier, A.H. Assembly and activation of HK-PK complex on endothelial cells results in bradykinin liberation and NO formation. *Am. J. Physiol. Heart Circ. Physiol.* **2001**, *280*, H1821–H1829. [[CrossRef](#)]
59. Baglia, F.A.; Gailani, D.; Lopez, J.A.; Walsh, P.N. Identification of a binding site for glycoprotein Ibalpha in the Apple 3 domain of factor XI. *J. Biol. Chem.* **2004**, *279*, 45470–45476. [[CrossRef](#)] [[PubMed](#)]
60. Versteeg, H.H.; Heemskerk, J.W.; Levi, M.; Reitsma, P.H. New fundamentals in hemostasis. *Physiol. Rev.* **2013**, *93*, 327–358. [[CrossRef](#)] [[PubMed](#)]
61. Marx, G. Zinc binding to fibrinogen and fibrin. *Arch. Biochem. Biophys.* **1988**, *266*, 285–288. [[CrossRef](#)]
62. Gailani, D.; Renne, T. The intrinsic pathway of coagulation: A target for treating thromboembolic disease? *J. Thromb. Haemost.* **2007**, *5*, 1106–1112. [[CrossRef](#)] [[PubMed](#)]
63. Henderson, S.J.; Stafford, A.R.; Leslie, B.A.; Kim, P.Y.; Vaezzadeh, N.; Ni, R.; Fredenburgh, J.C.; Weitz, J.I. Zinc delays clot lysis by attenuating plasminogen activation and plasmin-mediated fibrin degradation. *Thromb. Haemost.* **2015**, *113*, 1278–1288. [[CrossRef](#)]
64. Henderson, S.J.; Xia, J.; Wu, H.; Stafford, A.R.; Leslie, B.A.; Fredenburgh, J.C.; Weitz, D.A.; Weitz, J.I. Zinc promotes clot stability by accelerating clot formation and modifying fibrin structure. *Thromb. Haemost.* **2016**, *115*, 533–542. [[CrossRef](#)] [[PubMed](#)]
65. Chan, H.H.; Stafford, A.R.; Leslie, B.A.; Fredenburgh, J.C.; Weitz, J.I. Zinc Enhances the Protection of Fibrin-Bound Thrombin from Antithro Inhibition. *Blood* **2007**, *110*, 2691. [[CrossRef](#)]
66. Bradford, H.N.; Pixley, R.A.; Colman, R.W. Human factor XII binding to the glycoprotein Ib-IX-V complex inhibits thrombin-induced platelet aggregation. *J. Biol. Chem.* **2000**, *275*, 22756–22763. [[CrossRef](#)] [[PubMed](#)]
67. Lundblad, R.L.; White, G.C. The interaction of thrombin with blood platelets. *Platelets* **2005**, *16*, 373–385. [[CrossRef](#)]
68. Bal, W.; Sokolowska, M.; Kurowska, E.; Faller, P. Binding of transition metal ions to albumin: Sites, affinities and rates. *Biochim. Biophys. Acta* **2013**, *1830*, 5444–5455. [[CrossRef](#)]
69. Yaseen, Z.; Aswal, V.; Zhou, X.; Haider, S. Morphological changes in human serum albumin in the presence of cationic amphiphilic drugs. *New J. Chem.* **2018**, *42*, 2270–2277. [[CrossRef](#)]
70. Lu, J.; Stewart, A.J.; Sadler, P.J.; Pinheiro, T.J.; Blindauer, C.A. Albumin as a zinc carrier: Properties of its high-affinity zinc-binding site. *Biochem. Soc. Trans.* **2008**, *36*, 1317–1321. [[CrossRef](#)] [[PubMed](#)]
71. Blindauer, C.A.; Harvey, I.; Bunyan, K.E.; Stewart, A.J.; Sleep, D.; Harrison, D.J.; Berezenko, S.; Sadler, P.J. Structure, properties, and engineering of the major zinc binding site on human albumin. *J. Biol. Chem.* **2009**, *284*, 23116–23124. [[CrossRef](#)]
72. Handing, K.B.; Shabalin, I.G.; Kassaar, O.; Khazaipoul, S.; Blindauer, C.A.; Stewart, A.J.; Chruszcz, M.; Minor, W. Circulatory zinc transport is controlled by distinct interdomain sites on mammalian albumins. *Chem. Sci.* **2016**, *7*, 6635–6648. [[CrossRef](#)]
73. Fasano, M.; Curry, S.; Terreno, E.; Galliano, M.; Fanali, G.; Narciso, P.; Notari, S.; Ascenzi, P. The extraordinary ligand binding properties of human serum albumin. *IUBMB Life* **2005**, *57*, 787–796. [[CrossRef](#)] [[PubMed](#)]
74. Paar, M.; Fengler, V.H.; Rosenberg, D.J.; Krebs, A.; Stauber, R.E.; Oettl, K.; Hammel, M. Albumin in patients with liver disease shows an altered conformation. *Commun. Biol.* **2021**, *4*, 1–9. [[CrossRef](#)] [[PubMed](#)]
75. Iqbal, S.; Qais, F.A.; Alam, M.M.; Naseem, I. Effect of glycation on human serum albumin-zinc interaction: A biophysical study. *J. Biol. Inorg. Chem.* **2018**, *23*, 447–458. [[CrossRef](#)]
76. Bhat, S.; Jagadeeshaprasad, M.G.; Venkatasubramani, V.; Kulkarni, M.J. Abundance matters: Role of albumin in diabetes, a proteomics perspective. *Expert Rev. Proteom.* **2017**, *14*, 677–689. [[CrossRef](#)]

77. Coussons, P.J.; Jacoby, J.; McKay, A.; Kelly, S.M.; Price, N.C.; Hunt, J.V. Glucose modification of human serum albumin: A structural study. *Free Radic. Biol. Med.* **1997**, *22*, 1217–1227. [[CrossRef](#)]
78. Dolhofer, R.; Wieland, O.H. Increased glycosylation of serum albumin in diabetes mellitus. *Diabetes* **1980**, *29*, 417–422. [[CrossRef](#)]
79. Rondeau, P.; Bourdon, E. The glycation of albumin: Structural and functional impacts. *Biochimie* **2011**, *93*, 645–658. [[CrossRef](#)] [[PubMed](#)]
80. Sattarahmady, N.; Moosavi-Movahedi, A.A.; Habibi-Rezaei, M.; Ahmadian, S.; Saboury, A.A.; Heli, H.; Sheibani, N. Detergency effects of nanofibrillar amyloid formation on glycation of human serum albumin. *Carbohydr. Res.* **2008**, *343*, 2229–2234. [[CrossRef](#)] [[PubMed](#)]
81. Miyamoto, H.; Kohzuma, T.; Ohnishi, A. Changes in the albumin glycation site, plasma pentosidine and esRAGE concentrations before and after intensive diabetic treatment in patients with abnormally high glycated albumin levels. *Ann. Clin. Biochem.* **2018**, *55*, 84–91. [[CrossRef](#)]
82. Jacobs, M.J.; Pinger, C.W.; Castiaux, A.D.; Maloney, K.J.; Spence, D.M. A novel 3D-printed centrifugal ultrafiltration method reveals in vivo glycation of human serum albumin decreases its binding affinity for zinc. *Metallomics* **2020**, *12*, 1036–1043. [[CrossRef](#)]
83. Chuang, V.T.G.; Otagiri, M. How do fatty acids cause allosteric binding of drugs to human serum albumin? *Pharm. Res.* **2002**, *19*, 1458–1464. [[CrossRef](#)] [[PubMed](#)]
84. Dasgupta, A.; Crossey, M.J. Elevated free fatty acid concentrations in lipemic sera reduce protein binding of valproic acid significantly more than phenytoin. *Am. J. Med. Sci.* **1997**, *313*, 75–79.
85. Takamura, N.; Shinozawa, S.; Maruyama, T.; Suenaga, A.; Otagiri, M. Effects of fatty acids on serum binding between furosemide and valproic acid. *Biol. Pharm. Bull.* **1998**, *21*, 174–176. [[CrossRef](#)] [[PubMed](#)]
86. Vorum, H.; Honore, B. Influence of fatty acids on the binding of warfarin and phenprocoumon to human serum albumin with relation to anticoagulant therapy. *J. Pharm. Pharmacol.* **1996**, *48*, 870–875. [[CrossRef](#)] [[PubMed](#)]
87. Barnett, J.P.; Blindauer, C.A.; Kassar, O.; Khazaipoul, S.; Martin, E.M.; Sadler, P.J.; Stewart, A.J. Allosteric modulation of zinc speciation by fatty acids. *Biochim. Biophys. Acta* **2013**, *1830*, 5456–5464. [[CrossRef](#)]
88. Sobczak, A.I.S.; Katundu, K.G.H.; Phoenix, F.A.; Khazaipoul, S.; Yu, R.; Lampiao, F.; Stefanowicz, F.; Blindauer, C.A.; Pitt, S.J.; Smith, T.K.; et al. Albumin-mediated alteration of plasma zinc speciation by fatty acids modulates blood clotting in type-2 diabetes. *Chem. Sci.* **2021**, *12*, 4079–4093. [[CrossRef](#)]
89. Maares, M.; Haase, H. A guide to human zinc absorption: General overview and recent advances of in vitro intestinal models. *Nutrients* **2020**, *12*, 762. [[CrossRef](#)]
90. Jones, A.L.; Hulett, M.D.; Parish, C.R. Histidine-rich glycoprotein: A novel adaptor protein in plasma that modulates the immune, vascular and coagulation systems. *Immunol. Cell Biol.* **2005**, *83*, 106–118. [[CrossRef](#)]
91. Leung, L.; Harpel, P.C.; Nachman, R.L.; Rabellino, E.M. Histidine-rich glycoprotein is present in human platelets and is released following thrombin stimulation. *Blood* **1983**, *62*, 1016–1021. [[CrossRef](#)]
92. Castaman, G.; Ruggeri, M.; Burei, F.; Rodeghiero, F. High levels of histidine-rich glycoprotein and thrombotic diathesis. Report of two unrelated families. *Thromb. Res.* **1993**, *69*, 297–305. [[CrossRef](#)]
93. Siudut, J.; Natarska, J.; Son, M.; Plens, K.; Undas, A. Increased levels of histidine-rich glycoprotein are associated with the development of post-thrombotic syndrome. *Sci. Rep.* **2020**, *10*, 14419. [[CrossRef](#)] [[PubMed](#)]
94. Kassar, O.; Schwarz-Linek, U.; Blindauer, C.A.; Stewart, A.J. Plasma free fatty acid levels influence Zn²⁺-dependent histidine-rich glycoprotein–heparin interactions via an allosteric switch on serum albumin. *J. Thromb. Haemost.* **2015**, *13*, 101–110. [[CrossRef](#)] [[PubMed](#)]
95. Kluszynski, B.A.; Kim, C.; Faulk, W.P. Zinc as a cofactor for heparin neutralization by histidine-rich glycoprotein. *J. Biol. Chem.* **1997**, *272*, 13541–13547. [[CrossRef](#)] [[PubMed](#)]
96. Priebatsch, K.M.; Kvensakul, M.; Poon, I.K.; Hulett, M.D. Functional regulation of the plasma protein histidine-rich glycoprotein by Zn²⁺ in settings of tissue injury. *Biomolecules* **2017**, *7*, 22. [[CrossRef](#)] [[PubMed](#)]
97. Vu, T.T.; Stafford, A.R.; Leslie, B.A.; Kim, P.Y.; Fredenburgh, J.C.; Weitz, J.I. Histidine-rich glycoprotein binds fibrin(ogen) with high affinity and competes with thrombin for binding to the gamma'-chain. *J. Biol. Chem.* **2011**, *286*, 30314–30323. [[CrossRef](#)] [[PubMed](#)]
98. Fredenburgh, J.C.; Leslie, B.A.; Stafford, A.R.; Lim, T.; Chan, H.H.; Weitz, J.I. Zn²⁺ mediates high affinity binding of heparin to the alphaC domain of fibrinogen. *J. Biol. Chem.* **2013**, *288*, 29394–29402. [[CrossRef](#)] [[PubMed](#)]
99. Sussulini, A.; Kratzin, H.; Jahn, O.; Banzato, C.E.; Arruda, M.A.; Becker, J.S. Metallomics studies of human blood serum from treated bipolar disorder patients. *Anal. Chem.* **2010**, *82*, 5859–5864. [[CrossRef](#)]
100. Robinson, N.; Waldron, K.; Tottey, S.; Bessant, C. Metalloprotein metal pools: Identification and quantification by coupling native and non-native separations through principal component analysis. *Protoc. Exch.* **2008**. [[CrossRef](#)]
101. Koot, B.G.; Houwen, R.; Pot, D.J.; Nauta, J. Congenital analbuminaemia: Biochemical and clinical implications. A case report and literature review. *Eur. J. Pediatr.* **2004**, *163*, 664–670. [[CrossRef](#)]
102. Frizzell, N.; Baynes, J.W. Chelation therapy: Overlooked in the treatment and prevention of diabetes complications? *Future Med. Chem.* **2013**, *5*, 1075–1078. [[CrossRef](#)] [[PubMed](#)]
103. Logie, L.; Harthill, J.; Patel, K.; Bacon, S.; Hamilton, D.L.; Macrae, K.; McDougall, G.; Wang, H.H.; Xue, L.; Jiang, H.; et al. Cellular responses to the metal-binding properties of metformin. *Diabetes* **2012**, *61*, 1423–1433. [[CrossRef](#)]

104. Nagai, R.; Murray, D.B.; Metz, T.O.; Baynes, J.W. Chelation: A fundamental mechanism of action of AGE inhibitors, AGE breakers, and other inhibitors of diabetes complications. *Diabetes* **2012**, *61*, 549–559. [[CrossRef](#)]
105. Wihler, C.; Schafer, S.; Schmid, K.; Deemer, E.K.; Munch, G.; Bleich, M.; Busch, A.E.; Dingermann, T.; Somoza, V.; Baynes, J.W.; et al. Renal accumulation and clearance of advanced glycation end-products in type 2 diabetic nephropathy: Effect of angiotensin-converting enzyme and vasopeptidase inhibition. *Diabetologia* **2005**, *48*, 1645–1653. [[CrossRef](#)] [[PubMed](#)]
106. Lamas, G.A. Chelation therapy: A new look at an old treatment for heart disease, particularly in diabetics. *Circulation* **2015**, *131*, e505–e506. [[CrossRef](#)] [[PubMed](#)]
107. Avila, M.D.; Escolar, E.; Lamas, G.A. Chelation therapy after the trial to assess chelation therapy: Results of a unique trial. *Curr. Opin. Cardiol.* **2014**, *29*, 481–488. [[CrossRef](#)] [[PubMed](#)]
108. Lamas, G.A.; Goertz, C.; Boineau, R.; Mark, D.B.; Rozema, T.; Nahin, R.L.; Lindblad, L.; Lewis, E.F.; Drisko, J.; Lee, K.L.; et al. Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: The TACT randomized trial. *JAMA* **2013**, *309*, 1241–1250. [[CrossRef](#)]
109. Escolar, E.; Lamas, G.A.; Mark, D.B.; Boineau, R.; Goertz, C.; Rosenberg, Y.; Nahin, R.L.; Ouyang, P.; Rozema, T.; Magaziner, A.; et al. The effect of an EDTA-based chelation regimen on patients with diabetes mellitus and prior myocardial infarction in the Trial to Assess Chelation Therapy (TACT). *Circ. Cardiovasc. Qual. Outcomes* **2014**, *7*, 15–24. [[CrossRef](#)] [[PubMed](#)]
110. Lu, J.; Stewart, A.J.; Sleep, D.; Sadler, P.J.; Pinheiro, T.J.; Blindauer, C.A. A molecular mechanism for modulating plasma Zn speciation by fatty acids. *J. Am. Chem. Soc.* **2012**, *134*, 1454–1457. [[CrossRef](#)]
111. Buttar, H.S.; Li, T.; Ravi, N. Prevention of cardiovascular diseases: Role of exercise, dietary interventions, obesity and smoking cessation. *Exp. Clin. Cardiol.* **2005**, *10*, 229–249. [[PubMed](#)]
112. Kim, M.K.; Jang, E.H.; Hong, O.K.; Chun, H.J.; Yoo, S.J.; Baek, K.H.; Kim, W.; Kim, E.K.; Song, K.H.; Kwon, H.S. Changes in serum levels of bone morphogenic protein 4 and inflammatory cytokines after bariatric surgery in severely obese korean patients with type 2 diabetes. *Int. J. Endocrinol.* **2013**, *2013*, 681205. [[CrossRef](#)] [[PubMed](#)]
113. Soriguer, F.; Garcia-Serrano, S.; Garcia-Almeida, J.M.; Garrido-Sanchez, L.; Garcia-Arnes, J.; Tinahones, F.J.; Cardona, I.; Rivas-Marin, J.; Gallego-Perales, J.L.; Garcia-Fuentes, E. Changes in the serum composition of free-fatty acids during an intravenous glucose tolerance test. *Obesity* **2009**, *17*, 10–15. [[CrossRef](#)] [[PubMed](#)]
114. Kim, M.K.; Kim, W.; Kwon, H.S.; Baek, K.H.; Kim, E.K.; Song, K.H. Effects of bariatric surgery on metabolic and nutritional parameters in severely obese Korean patients with type 2 diabetes: A prospective 2-year follow up. *J. Diabetes Investig.* **2014**, *5*, 221–227. [[CrossRef](#)]
115. Fabbrini, E.; Tamboli, R.A.; Magkos, F.; Marks-Shulman, P.A.; Eckhauser, A.W.; Richards, W.O.; Klein, S.; Abumrad, N.N. Surgical removal of omental fat does not improve insulin sensitivity and cardiovascular risk factors in obese adults. *Gastroenterology* **2010**, *139*, 448–455. [[CrossRef](#)]
116. Patti, A.M.; Giglio, R.V.; Papanas, N.; Rizzo, M.; Rizvi, A.A. Future perspectives of the pharmacological management of diabetic dyslipidemia. *Expert Rev. Clin. Pharmacol.* **2019**, *12*, 129–143. [[CrossRef](#)]
117. Barter, P.J.; Rye, K.A. New Era of Lipid-Lowering Drugs. *Pharmacol. Rev.* **2016**, *68*, 458–475. [[CrossRef](#)] [[PubMed](#)]
118. Sahebkar, A.; Simental-Mendia, L.E.; Pedone, C.; Ferretti, G.; Nachtigal, P.; Bo, S.; Derosa, G.; Maffioli, P.; Watts, G.F. Statin therapy and plasma free fatty acids: A systematic review and meta-analysis of controlled clinical trials. *Br. J. Clin. Pharmacol.* **2016**, *81*, 807–818. [[CrossRef](#)]
119. Staels, B.; Dallongeville, J.; Auwerx, J.; Schoonjans, K.; Leitersdorf, E.; Fruchart, J.C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. *Circulation* **1998**, *98*, 2088–2093. [[CrossRef](#)] [[PubMed](#)]
120. Jonkers, I.J.; de Man, F.H.; van der Laarse, A.; Frolich, M.; Gevers Leuven, J.A.; Kamper, A.M.; Blauw, G.J.; Smelt, A.H. Bezafibrate reduces heart rate and blood pressure in patients with hypertriglyceridemia. *J. Hypertens.* **2001**, *19*, 749–755. [[CrossRef](#)] [[PubMed](#)]
121. Li, X.M.; Li, Y.; Zhang, N.N.; Xie, Y.H.; Shi, Y.Q. Combination therapy with metformin and fenofibrate for insulin resistance in obesity. *J. Int. Med. Res.* **2011**, *39*, 1876–1882. [[CrossRef](#)] [[PubMed](#)]
122. Sane, T.; Knudsen, P.; Vuorinen-Markkola, H.; Yki-Järvinen, H.; Taskinen, M.-R. Decreasing triglyceride by gemfibrozil therapy does not affect the glucoregulatory or antilipolytic effect of insulin in nondiabetic subjects with mild hypertriglyceridemia. *Metabolism* **1995**, *44*, 589–596. [[CrossRef](#)]
123. Alberti, K.G.; Jones, I.R.; Laker, M.F.; Swai, A.B.; Taylor, R. Effect of bezafibrate on metabolic profiles in non-insulin-dependent diabetes mellitus. *J. Cardiovasc. Pharmacol.* **1990**, *16* (Suppl. S9), S21–S24; S24–S25. [[CrossRef](#)]
124. Fenderson, R.W., Jr.; Sekowski, I.; Mohan, N.C.; Deutsch, S.; Benjamin, F.; Samuel, P. Effect of clofibrate on plasma glucose and serum immunoreactive insulin in patients with hyperlipoproteinemia. *Am. J. Clin. Nutr.* **1974**, *27*, 22–28. [[CrossRef](#)]
125. Avogaro, A.; Piliago, T.; Catapano, A.; Miola, M.; Tiengo, A. The effect of gemfibrozil on lipid profile and glucose metabolism in hypertriglyceridaemic well-controlled non-insulin-dependent diabetic patients. For the Gemfibrozil Study Group. *Acta Diabetol.* **1999**, *36*, 27–33. [[CrossRef](#)]
126. Matsuba, I.; Matsuba, R.; Ishibashi, S.; Yamashita, S.; Arai, H.; Yokote, K.; Suganami, H.; Araki, E. Effects of a novel selective peroxisome proliferator-activated receptor- α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance. *J. Diabetes Investig.* **2018**, *9*, 1323–1332. [[CrossRef](#)] [[PubMed](#)]
127. Calvert, G.D.; Blight, L.; Franklin, J.; Oliver, J.; Wise, P.; Gallus, A.S. The effects of clofibrate on plasma glucose, lipoproteins, fibrinogen, and other biochemical and haematological variables in patients with mature onset diabetes mellitus. *Eur. J. Clin. Pharmacol.* **1980**, *17*, 355–362. [[CrossRef](#)] [[PubMed](#)]

128. Mussoni, L.; Mannucci, L.; Sirtori, C.; Pazzucconi, F.; Bonfardeci, G.; Cimminiello, C.; Notarbartolo, A.; Scafidi, V.; Bon, G.B.; Alessandrini, P. Effects of gemfibrozil on insulin sensitivity and on haemostatic variables in hypertriglyceridemic patients. *Atherosclerosis* **2000**, *148*, 397–406. [[CrossRef](#)]
129. Vega, G.L.; Cater, N.B.; Hadizadeh III, D.R.; Meguro, S.; Grundy, S.M. Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome. *Clin. Pharmacol. Ther.* **2003**, *74*, 236–244. [[CrossRef](#)]
130. Jeng, C.Y.; Sheu, W.H.; Fuh, M.M.; Shieh, S.M.; Chen, Y.D.; Reaven, G.M. Gemfibrozil treatment of endogenous hypertriglyceridemia: Effect on insulin-mediated glucose disposal and plasma insulin concentrations. *J. Clin. Endocrinol. Metab.* **1996**, *81*, 2550–2553.
131. Avogaro, A.; Beltramello, P.; Marin, R.; Zambon, S.; Bonanome, A.; Biffanti, S.; Confortin, L.; Manzato, E.; Crepaldi, G.; Tiengo, A. Insulin action and glucose metabolism are improved by gemfibrozil treatment in hypertriglyceridemic patients. *Atherosclerosis* **1995**, *113*, 117–124. [[CrossRef](#)]
132. Jones, I.R.; Swai, A.; Taylor, R.; Miller, M.; Laker, M.F.; Alberti, K.G. Lowering of plasma glucose concentrations with bezafibrate in patients with moderately controlled NIDDM. *Diabetes Care* **1990**, *13*, 855–863. [[CrossRef](#)]
133. Vuorinen-Markkola, H.; Yki-Järvinen, H.; Taskinen, M.-R. Lowering of triglycerides by gemfibrozil affects neither the glucoregulatory nor antilipolytic effect of insulin in type 2 (non-insulin-dependent) diabetic patients. *Diabetologia* **1993**, *36*, 161–169. [[CrossRef](#)] [[PubMed](#)]
134. Capell, W.H.; DeSouza, C.A.; Poirier, P.; Bell, M.L.; Stauffer, B.L.; Weil, K.M.; Hernandez, T.L.; Eckel, R.H. Short-term triglyceride lowering with fenofibrate improves vasodilator function in subjects with hypertriglyceridemia. *Arterioscler. Thromb. Vasc. Biol.* **2003**, *23*, 307–313. [[CrossRef](#)]
135. Sanchez-Rangel, E.; Inzucchi, S.E. Metformin: Clinical use in type 2 diabetes. *Diabetologia* **2017**, *60*, 1586–1593. [[CrossRef](#)]
136. Fruehwald-Schultes, B.; Oltmanns, K.M.; Toschek, B.; Sopke, S.; Kern, W.; Born, J.; Fehm, H.L.; Peters, A. Short-term treatment with metformin decreases serum leptin concentration without affecting body weight and body fat content in normal-weight healthy men. *Metabolism* **2002**, *51*, 531–536. [[CrossRef](#)] [[PubMed](#)]
137. Gormsen, L.C.; Søndergaard, E.; Christensen, N.L.; Jakobsen, S.; Nielsen, E.H.; Munk, O.L.; Tolbod, L.P.; Jessen, N.; Nielsen, S. Metformin does not affect postabsorptive hepatic free fatty acid uptake, oxidation or resecretion in humans: A 3-month placebo-controlled clinical trial in patients with type 2 diabetes and healthy controls. *Diabetes Obes. Metab.* **2018**, *20*, 1435–1444. [[CrossRef](#)] [[PubMed](#)]
138. Lehtovirta, M.; Forsen, B.; Gullstrom, M.; Hagglom, M.; Eriksson, J.G.; Taskinen, M.R.; Groop, L. Metabolic effects of metformin in patients with impaired glucose tolerance. *Diabet. Med.* **2001**, *18*, 578–583. [[CrossRef](#)]
139. Pentikäinen, P.J.; Voutilainen, E.; Aro, A.; Uusitupa, M.; Penttilä, I.; Vapaatalo, H. Cholesterol lowering effect of metformin in combined hyperlipidemia: Placebo controlled double blind trial. *Ann. Med.* **1990**, *22*, 307–312. [[CrossRef](#)] [[PubMed](#)]
140. Boussageon, R.; Supper, I.; Bejan-Angoulvant, T.; Kellou, N.; Cucherat, M.; Boissel, J.P.; Kassai, B.; Moreau, A.; Gueyffier, F.; Cornu, C. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: A meta-analysis of randomised controlled trials. *PLoS Med.* **2012**, *9*, e1001204. [[CrossRef](#)] [[PubMed](#)]
141. Griffin, S.J.; Leaver, J.K.; Irving, G.J. Impact of metformin on cardiovascular disease: A meta-analysis of randomised trials among people with type 2 diabetes. *Diabetologia* **2017**, *60*, 1620–1629. [[CrossRef](#)]
142. Gurgle, H.E.; White, K.; McAdam-Marx, C. SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: Patient selection and perspectives. *Vasc. Health Risk Manag.* **2016**, *12*, 239.
143. Lopaschuk, G.D.; Verma, S. Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review. *JACC Basic Transl. Sci.* **2020**, *5*, 632–644. [[CrossRef](#)] [[PubMed](#)]
144. Patel, D.K.; Strong, J. The Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit. *Diabetes Ther.* **2019**, *10*, 1771–1792. [[CrossRef](#)]
145. Bramante, C.T.; Raatz, S.; Bomberg, E.M.; Oberle, M.M.; Ryder, J.R. Cardiovascular risks and benefits of medications used for weight loss. *Front. Endocrinol.* **2020**, *10*, 883. [[CrossRef](#)] [[PubMed](#)]
146. Marso, S.P.; Daniels, G.H.; Brown-Frandsen, K.; Kristensen, P.; Mann, J.F.; Nauck, M.A.; Nissen, S.E.; Pocock, S.; Poulter, N.R.; Ravn, L.S. Liraglutide and cardiovascular outcomes in type 2 diabetes. *N. Engl. J. Med.* **2016**, *375*, 311–322. [[CrossRef](#)] [[PubMed](#)]
147. Sun, F.; Wu, S.; Guo, S.; Yu, K.; Yang, Z.; Li, L.; Zhang, Y.; Quan, X.; Ji, L.; Zhan, S. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis. *Diabetes Res. Clin. Pract.* **2015**, *110*, 26–37. [[CrossRef](#)] [[PubMed](#)]
148. Plutzky, J.; Garber, A.; Falahati, A.; Toft, A.D.; Poulter, N.R. Reductions in lipids and CV risk markers in patients with type 2 diabetes treated with liraglutide: A meta-analysis. *Can. J. Diabetes* **2009**, *33*, 209–210. [[CrossRef](#)]
149. Roder, M.E. Major adverse cardiovascular event reduction with GLP-1 and SGLT2 agents: Evidence and clinical potential. *Ther. Adv. Chronic Dis.* **2018**, *9*, 33–50. [[CrossRef](#)] [[PubMed](#)]
150. Wanner, C.; Lachin, J.M.; Fitchett, D.; Bluhmki, E.; Hantel, S.; Mattheus, M.; Devins, T.; Johansen, O.E.; Woerle, H.J.; Zinman, B.; et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *N. Engl. J. Med.* **2015**, *373*, 2117–2128.
151. Osataphan, S.; Macchi, C.; Singhal, G.; Chimene-Weiss, J.; Sales, V.; Kozuka, C.; Dreyfuss, J.M.; Pan, H.; Tangcharoenpaisan, Y.; Morningstar, J.; et al. SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms. *JCI Insight* **2019**, *4*, e123130. [[CrossRef](#)] [[PubMed](#)]